• Alexion Partners with Genomenon to Deliver Detailed, Curated Variant Data to Speed Diagnosis

    Oct 21 | Diagnostics World News | Most rare diseases have a genetic component, yet most people with rare diseases remain undiagnosed, Thomas Defay, Alexion Pharmaceuticals, told the audience at the Bio-IT World Conference & Expo last month. Alexion has partnered with Genomenon to build out curated dashboards specific to some of Alexion’s genetic diseases of interest. More
  • Scratch-and-Sniff: Smell Tests Aim to Curb COVID Spread

    Oct 19 | Diagnostics World | Several research groups and start-ups are pursuing the potential of scratch-and-sniff testing, envisioning it as a simple, cheap, and accessible tool that could help limit transmission and avoid shutdowns during the next phase of the coronavirus pandemic. More
  • Is a Labor Shortage Delaying Your Biopsy Results?

    Oct 15 | Diagnostics World News | No one awaiting the results of a biopsy wants to hear that they may be in for a longer wait. But, there’s a good chance results may be delayed and there is an understandable reason for it: There are tens of millions of biopsies ordered each year, and there aren’t enough histotechnologists to process them. More
  • Cancers And Sepsis Being Targeted By cfDNA Liquid Biopsies

    Oct 13 | Bio-IT World | Researchers at Washington University (WashU) are exploring use of cell-free DNA (cfDNA) as a liquid biopsy analyte for solid tumors and, most recently, to track and predict organ damage causes by sepsis. Particularly noteworthy is their liquid biopsy for distinguishing between benign and malignant tumors in a heritable cancer predisposition syndrome. More
  • Follow the Money: COVID-19 Consumables, Imaging Data Analysis

    Oct 11 | Diagnostics World News | Several investments to improve the COVID-19 testing supply chain, funding acquisitions for image data analysis, personalized medicine plans, seed round for medical genetics software, and more. More
  • NFL Partners on Brain Health, AI in Diagnostics, COVID-19 Detection

    Oct 07 | Diagnostics World News | New assays for COVID-19 detection and partnerships to increase testing; AI detection tools for prostate cancer, inflammatory bowel disease, rare diseases; and diagnostic partnerships with AstraZeneca, Mount Sinai, and Merck. Plus new products from Proscia, Seegene, Thermo Fisher, Sensyne Health, and more. More
  • EUA to Approved Pipeline for COVID-19 Tests

    Oct 06 | Diagnostics World News | The U.S. Food and Drug Administration (FDA) has fast-tracked tests under Emergency Use Authorization (EUA) during the coronavirus pandemic. Along the way, there has been a flurry of activity in a short time. But what will happen to the many COVID-19 tests that have been issued EUAs once the public health emergency winds down? Diagnostics World gathered insight from the FDA and several companies to learn more about the road ahead. More
  • Biomarkers Give Clinical Trials of Neurodegenerative Diseases a Head Start

    Oct 01 | Diagnostics World News | Accurate diagnosis and monitoring of neurodegenerative diseases are complicated by a patient’s delayed clinical symptoms, which often appear decades after molecular disease onset. Biomarkers that detect the molecular changes preceding the clinical symptoms of neurodegenerative disease are critical for clinical trials at pre-symptomatic stages, effective diagnostics and the subsequent development of preventive therapies. More
  • Microwave Sensor Could Enable Personalized Antibiotic Therapy

    Sep 29 | Diagnostics World News | Researchers at the University of British Columbia (UBC) are developing microwave sensing devices that communicate with molecules to detect the presence of bacteria, as well as their growth pace and response to antibiotics—and deliver the information in about six hours. More
  • Biochip Platform Could Enable Personalized Immunotherapy

    Sep 27 | Diagnostics World News | Rensselaer Polytechnic Institute and South Korean biotech Medical & Bio Decision Company Ltd. (MBD) are working on turning a biochip into a personalized immunotherapy platform for rapidly screening a wide range of treatment cocktails for individual cancer patients. The platform would be ideally suited for very small tumor biopsy samples. More
View more articles

 
DXX-Industry-spotlight

Acrobiosystems

Antigens & Antibodies for SARS-CoV-2 Diagnostic Kit Development

ACROBiosystems team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of high-quality antigen and antibody reagents to support the development of the diagnostic kits. The products include the high quality S trimer, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity tested on several platforms.

Click to learn more about ACRO’s hot matched antibody pairs and antigens.